Oric Pharmaceuticals, Inc. ORIC
We take great care to ensure that the data presented and summarized in this overview for Oric Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ORIC
View all-
Nextech Invest Ag5.29MShares$47.4 Million8.84% of portfolio
-
Black Rock Inc. New York, NY4.83MShares$43.3 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY4.39MShares$39.4 Million4.67% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA4.14MShares$37.1 Million2.29% of portfolio
-
Viking Global Investors LP4MShares$35.8 Million0.16% of portfolio
-
Alkeon Capital Management LLC New York, NY3.9MShares$35 Million0.07% of portfolio
-
Column Group LLC San Francisco, CA3.54MShares$31.7 Million52.2% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.42MShares$30.6 Million1.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.17MShares$28.4 Million0.0% of portfolio
-
Commodore Capital LP New York, NY2MShares$17.9 Million1.74% of portfolio
Latest Institutional Activity in ORIC
Top Purchases
Top Sells
About ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Insider Transactions at ORIC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
24,660
-3.07%
|
$197,280
$8.28 P/Share
|
|
Dec 16
2024
|
Pratik S Multani Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,850
-15.91%
|
$70,800
$8.28 P/Share
|
|
Dec 16
2024
|
Dominic Piscitelli Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,851
-7.66%
|
$70,808
$8.28 P/Share
|
|
Dec 15
2024
|
Jacob Chacko PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
67,000
+7.7%
|
-
|
|
Dec 15
2024
|
Pratik S Multani Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,042
+30.18%
|
-
|
|
Dec 15
2024
|
Dominic Piscitelli Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,042
+17.22%
|
-
|
|
Jun 03
2024
|
Lori Anne Kunkel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,500
+50.0%
|
$61,500
$3.75 P/Share
|
|
Mar 06
2024
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
40,000
-5.2%
|
$640,000
$16.21 P/Share
|
|
Feb 07
2024
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
26,042
-3.28%
|
$312,504
$12.29 P/Share
|
|
Feb 06
2024
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
13,958
-1.73%
|
$167,496
$12.12 P/Share
|
|
Dec 15
2023
|
Dominic Piscitelli Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,282
-5.93%
|
$42,256
$8.58 P/Share
|
|
Dec 15
2023
|
Dominic Piscitelli Chief Financial Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
14,042
-13.62%
|
-
|
|
Dec 15
2023
|
Pratik S Multani Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,282
-18.16%
|
$42,256
$8.59 P/Share
|
|
Dec 15
2023
|
Pratik S Multani Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,042
+32.56%
|
-
|
|
Dec 15
2023
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
14,539
-1.77%
|
$116,312
$8.58 P/Share
|
|
Dec 15
2023
|
Jacob Chacko PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,667
+4.49%
|
-
|
|
Jul 11
2023
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
5,156
-0.66%
|
$41,248
$8.01 P/Share
|
|
Jul 10
2023
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
10,508
-1.32%
|
$84,064
$8.01 P/Share
|
|
Jul 05
2023
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
4,336
-0.54%
|
$34,688
$8.01 P/Share
|
|
Jun 26
2023
|
Jacob Chacko PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
20,000
-2.44%
|
$160,000
$8.03 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 136K shares |
|---|
| Open market or private sale | 122K shares |
|---|